Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.65
CRIS's Cash to Debt is ranked lower than
67% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. CRIS: 3.65 )
Ranked among companies with meaningful Cash to Debt only.
CRIS' s 10-Year Cash to Debt Range
Min: 1.68   Max: No Debt
Current: 3.65

Equity to Asset 0.73
CRIS's Equity to Asset is ranked higher than
56% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRIS: 0.73 )
Ranked among companies with meaningful Equity to Asset only.
CRIS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.95
Current: 0.73

0.12
0.95
F-Score: 3
Z-Score: -2.26
M-Score: -3.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -412.36
CRIS's Operating margin (%) is ranked lower than
71% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -73.33 vs. CRIS: -412.36 )
Ranked among companies with meaningful Operating margin (%) only.
CRIS' s 10-Year Operating margin (%) Range
Min: -6639.83   Max: -35.24
Current: -412.36

-6639.83
-35.24
Net-margin (%) -440.57
CRIS's Net-margin (%) is ranked lower than
72% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. CRIS: -440.57 )
Ranked among companies with meaningful Net-margin (%) only.
CRIS' s 10-Year Net-margin (%) Range
Min: -35140.52   Max: -27.72
Current: -440.57

-35140.52
-27.72
ROE (%) -97.01
CRIS's ROE (%) is ranked lower than
81% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. CRIS: -97.01 )
Ranked among companies with meaningful ROE (%) only.
CRIS' s 10-Year ROE (%) Range
Min: -364.5   Max: -11.29
Current: -97.01

-364.5
-11.29
ROA (%) -56.35
CRIS's ROA (%) is ranked lower than
75% of the 836 Companies
in the Global Biotechnology industry.

( Industry Median: -23.47 vs. CRIS: -56.35 )
Ranked among companies with meaningful ROA (%) only.
CRIS' s 10-Year ROA (%) Range
Min: -331.19   Max: -10.23
Current: -56.35

-331.19
-10.23
ROC (Joel Greenblatt) (%) -7467.39
CRIS's ROC (Joel Greenblatt) (%) is ranked lower than
85% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -358.68 vs. CRIS: -7467.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CRIS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4184.27   Max: -206.43
Current: -7467.39

-4184.27
-206.43
Revenue Growth (3Y)(%) -16.70
CRIS's Revenue Growth (3Y)(%) is ranked lower than
65% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. CRIS: -16.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CRIS' s 10-Year Revenue Growth (3Y)(%) Range
Min: -40.5   Max: 72.9
Current: -16.7

-40.5
72.9
EBITDA Growth (3Y)(%) 9.40
CRIS's EBITDA Growth (3Y)(%) is ranked higher than
64% of the 426 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. CRIS: 9.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CRIS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -49.4   Max: 26
Current: 9.4

-49.4
26
EPS Growth (3Y)(%) 19.20
CRIS's EPS Growth (3Y)(%) is ranked higher than
77% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CRIS: 19.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CRIS' s 10-Year EPS Growth (3Y)(%) Range
Min: -74.5   Max: 35.7
Current: 19.2

-74.5
35.7
» CRIS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CRIS Guru Trades in Q2 2014

George Soros 44,000 sh (New)
Jim Simons 511,600 sh (New)
First Eagle Investment 19,468,451 sh (+8.54%)
» More
Q3 2014

CRIS Guru Trades in Q3 2014

Paul Tudor Jones 21,463 sh (New)
First Eagle Investment 19,568,451 sh (+0.51%)
George Soros Sold Out
Jim Simons Sold Out
» More
Q4 2014

CRIS Guru Trades in Q4 2014

First Eagle Investment 20,617,445 sh (+5.36%)
First Eagle Investment 20,372,372 sh (+4.11%)
Paul Tudor Jones 21,463 sh (unchged)
» More
Q1 2015

CRIS Guru Trades in Q1 2015

Leon Cooperman 300,000 sh (New)
Steven Cohen 100,000 sh (New)
Jim Simons 324,600 sh (New)
Paul Tudor Jones 60,263 sh (+180.78%)
First Eagle Investment 24,008,672 sh (+17.85%)
First Eagle Investment 24,008,672 sh (+17.85%)
» More
» Details

Insider Trades

Latest Guru Trades with CRIS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Curis Inc

First Eagle Increases Holdings of Spin-Off and Cancer Drug Company
The $100 billion investment firm First Eagle Funds has grown its already significant interest in two companies: Curis Inc. (CRIS) and Vista Outdoor Inc. (VSTO), GuruFocus Real Time Picks reported. Read more...

Ratios

vs
industry
vs
history
P/B 5.20
CRIS's P/B is ranked higher than
51% of the 1028 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. CRIS: 5.20 )
Ranked among companies with meaningful P/B only.
CRIS' s 10-Year P/B Range
Min: 1.15   Max: 10.95
Current: 5.2

1.15
10.95
P/S 31.50
CRIS's P/S is ranked lower than
71% of the 1029 Companies
in the Global Biotechnology industry.

( Industry Median: 11.92 vs. CRIS: 31.50 )
Ranked among companies with meaningful P/S only.
CRIS' s 10-Year P/S Range
Min: 2.69   Max: 382
Current: 31.5

2.69
382
Current Ratio 10.54
CRIS's Current Ratio is ranked higher than
76% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. CRIS: 10.54 )
Ranked among companies with meaningful Current Ratio only.
CRIS' s 10-Year Current Ratio Range
Min: 2.89   Max: 25.89
Current: 10.54

2.89
25.89
Quick Ratio 10.54
CRIS's Quick Ratio is ranked higher than
77% of the 809 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. CRIS: 10.54 )
Ranked among companies with meaningful Quick Ratio only.
CRIS' s 10-Year Quick Ratio Range
Min: 2.89   Max: 25.89
Current: 10.54

2.89
25.89
Days Sales Outstanding 63.20
CRIS's Days Sales Outstanding is ranked higher than
50% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 63.44 vs. CRIS: 63.20 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRIS' s 10-Year Days Sales Outstanding Range
Min: 1.04   Max: 131.06
Current: 63.2

1.04
131.06

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.60
CRIS's Price/Net Cash is ranked higher than
64% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 9.70 vs. CRIS: 6.60 )
Ranked among companies with meaningful Price/Net Cash only.
CRIS' s 10-Year Price/Net Cash Range
Min: 1.78   Max: 21.58
Current: 6.6

1.78
21.58
Price/Net Current Asset Value 6.50
CRIS's Price/Net Current Asset Value is ranked higher than
64% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 15.30 vs. CRIS: 6.50 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CRIS' s 10-Year Price/Net Current Asset Value Range
Min: 1.75   Max: 16.62
Current: 6.5

1.75
16.62
Price/Tangible Book 5.70
CRIS's Price/Tangible Book is ranked higher than
52% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: 5.70 vs. CRIS: 5.70 )
Ranked among companies with meaningful Price/Tangible Book only.
CRIS' s 10-Year Price/Tangible Book Range
Min: 1.63   Max: 15.25
Current: 5.7

1.63
15.25
Price/Median PS Value 2.00
CRIS's Price/Median PS Value is ranked lower than
66% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. CRIS: 2.00 )
Ranked among companies with meaningful Price/Median PS Value only.
CRIS' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 22.57
Current: 2

0.09
22.57
Earnings Yield (Greenblatt) -11.30
CRIS's Earnings Yield (Greenblatt) is ranked lower than
64% of the 1030 Companies
in the Global Biotechnology industry.

( Industry Median: -6.70 vs. CRIS: -11.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
CRIS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -12.9   Max: 1.1
Current: -11.3

-12.9
1.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CUS.Germany,
Curis Inc was organized as a Delaware corporation on February 14, 2000. It began its operations in July 2000 upon the completion of the merger of Creative BioMolecules, Inc., Ontogeny, Inc. and Reprogenesis, Inc. The Company is a drug discovery and development company that leverages its signaling pathway drug technologies to develop next generation targeted cancer therapies. The Company's advanced program is its Hedgehog pathway inhibitor program under collaboration with Genentech, Inc., a wholly-owned member of the Roche Group. The drug candidate being developed under this program is Erivedge, an orally-administered small molecule Hedgehog pathway inhibitor, which is also referred to as vismodegib, GDC-0449 and RG3616. Erivedge is designed to selectively inhibit signaling in the Hedgehog pathway by targeting a protein called Smoothened. The Hedgehog signaling pathway plays an important role in regulating proper growth and development in the early stages of life and becomes less active in adults. In addition to the BCC clinical trials being conducted directly by Genentech and Roche, Erivedge is also currently being tested in other cancers in trials under collaborative agreements between Genentech and either third-party investigators or the U.S. National Cancer Institute. In addition to the ongoing clinical trials that Genentech and Roche are conducting, Genentech and the National Cancer Institute, entered into a collaborative relationship that allows the NCI to study GDC-0449 in additional potential cancer indications. The Company has in the U.S., 97 issued or allowed patents. The Company's competitors include large pharmaceutical and biopharmaceutical companies, as well as specialized biotechnology firms, that are developing cancer therapies in the same indications as it is. The Company is subject to government regulations.
» More Articles for CRIS

Headlines

Articles On GuruFocus.com
Roth Capital Weighs In On 5 Biotech Stocks to Watch Apr 05 2015 
ciazek stock Mar 28 2015 
First Eagle Increases Holdings of Spin-Off and Cancer Drug Company Mar 10 2015 
Cowen & Co Remains Bullish on Celldex Therapeutics Following FDA 'Breakthrough' Approval Feb 24 2015 
What the Gurus Did This Week - Weekly Update on Guru Real Time Activity Jun 14 2013 
Weekly CFO Sells Highlight: USB, GNC, WWWW, GWRE, CRIS, CSL Apr 30 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
Weekly CEO Sells Highlight: MU, CRIS, HIL, and AMRS Apr 03 2011 
Curis Inc. Reports Operating Results (10-Q) Aug 03 2010 
cooldecency99 note on CRIS May 01 2010 

More From Other Websites
2:35 am Curis reports CUDC-907 data from the ongoing Phase 1 trial Jun 01 2015
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting May 31 2015
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting May 31 2015
CURIS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... May 28 2015
Curis to Present at the Jefferies 2015 Healthcare Conference May 27 2015
Curis to Present at the Jefferies 2015 Healthcare Conference May 27 2015
Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting May 20 2015
Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting May 20 2015
CURIS INC Financials May 16 2015
10-Q for Curis, Inc. May 09 2015
CURIS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 07 2015
Curis reports 1Q loss May 07 2015
Curis reports 1Q loss May 07 2015
Q1 2015 Curis Inc Earnings Release - Before Market Open May 07 2015
Curis Reports First Quarter 2015 Financial Results May 07 2015
Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015 Apr 30 2015
Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015 Apr 30 2015
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting Apr 22 2015
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting Apr 22 2015
American Association for Cancer Research (AACR) Annual Meeting 2015 Apr 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK